By building upon early observations of antihyperglycemic actions by GLP-1 and Gila monster exendin-4, exenatide was successfully developed into a diabetes therapeutic agent with a broad range of beneficial cardiometabolic effects and an acceptable tolerability profile. The gene discussed is GCG; the disease is diabetes mellitus.